Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available.
The global average price of Human Prothrombin Complex is in the increasing trend, from 124 USD/Unit in 2013 to 137 USD/Unit in 2017. With the situation of global economy, prices will be in increasing trend in the following five years.
The classification of Human Prothrombin Complex includes 500 IU/Vial, 600 IU/Vial, 1000 IU/Vial and others, and the proportion of 500 IU/Vial in 2017 is about 51%.
Human Prothrombin Complex is widely used in Hemophilia B, Vitamin K Deficiency and other diseases. The most proportion of Human Prothrombin Complex is Hemophilia B, and the proportion of sales is 48%.
North America is the largest consumption place, with a consumption market share nearly 46% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 33%.
Market competition is not intense. Shire, CSL, Grifols, Octapharma, Hualan Biological, Meheco Xinxing Pharma, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
Market Analysis and Insights: Global Human Prothrombin Complex Market
The global Human Prothrombin Complex market was valued at US$ 1588.3 in 2020 and will reach US$ 3101.6 million by the end of 2027, growing at a CAGR of 11.8% during 2022-2027.
Global Human Prothrombin Complex Scope and Market Size
The global Human Prothrombin Complex market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Human Prothrombin Complex market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
500 IU/Vial
600 IU/Vial
1000 IU/Vial
Others
Segment by Application
Hemophilia B
Vitamin K Deficiency
Others
The Human Prothrombin Complex market is analysed and market size information is provided by regions (countries). Segment by Application, the Human Prothrombin Complex market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Takeda
CSL
Grifols
Octapharma
Hualan Biological
Meheco Xinxing Pharma
The global average price of Human Prothrombin Complex is in the increasing trend, from 124 USD/Unit in 2013 to 137 USD/Unit in 2017. With the situation of global economy, prices will be in increasing trend in the following five years.
The classification of Human Prothrombin Complex includes 500 IU/Vial, 600 IU/Vial, 1000 IU/Vial and others, and the proportion of 500 IU/Vial in 2017 is about 51%.
Human Prothrombin Complex is widely used in Hemophilia B, Vitamin K Deficiency and other diseases. The most proportion of Human Prothrombin Complex is Hemophilia B, and the proportion of sales is 48%.
North America is the largest consumption place, with a consumption market share nearly 46% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 33%.
Market competition is not intense. Shire, CSL, Grifols, Octapharma, Hualan Biological, Meheco Xinxing Pharma, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
Market Analysis and Insights: Global Human Prothrombin Complex Market
The global Human Prothrombin Complex market was valued at US$ 1588.3 in 2020 and will reach US$ 3101.6 million by the end of 2027, growing at a CAGR of 11.8% during 2022-2027.
Global Human Prothrombin Complex Scope and Market Size
The global Human Prothrombin Complex market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Human Prothrombin Complex market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
500 IU/Vial
600 IU/Vial
1000 IU/Vial
Others
Segment by Application
Hemophilia B
Vitamin K Deficiency
Others
The Human Prothrombin Complex market is analysed and market size information is provided by regions (countries). Segment by Application, the Human Prothrombin Complex market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Takeda
CSL
Grifols
Octapharma
Hualan Biological
Meheco Xinxing Pharma
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
